Kaj Blennow

3.6k total papers · 230.7k total citations
2.0k papers, 121.6k citations indexed

About

Kaj Blennow is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Kaj Blennow has authored 2.0k papers receiving a total of 121.6k indexed citations (citations by other indexed papers that have themselves been cited), including 1.2k papers in Physiology, 841 papers in Psychiatry and Mental health and 478 papers in Molecular Biology. Recurrent topics in Kaj Blennow's work include Alzheimer's disease research and treatments (1.1k papers), Dementia and Cognitive Impairment Research (768 papers) and Neuroinflammation and Neurodegeneration Mechanisms (153 papers). Kaj Blennow is often cited by papers focused on Alzheimer's disease research and treatments (1.1k papers), Dementia and Cognitive Impairment Research (768 papers) and Neuroinflammation and Neurodegeneration Mechanisms (153 papers). Kaj Blennow collaborates with scholars based in Sweden, United Kingdom and United States. Kaj Blennow's co-authors include Henrik Zetterberg, Oskar Hansson, Harald Hampel, Niklas Mattsson, Lennart Minthon, Ulf Andréasson, Mony J. de Leon, Eugeen Vanmechelen, Niels Andreasen and Pia Davidsson and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Kaj Blennow

2.0k papers receiving 119.8k citations

Hit Papers

Alzheimer's disease 1995 2026 2005 2015 2006 2016 2009 2017 2010 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Alzheimer's disease
    2006 2.4k citations Kaj Blennow, Mony J. de Leon et al. The Lancet profile →
  2. Alzheimer's disease
    2016 2.4k citations Philip Scheltens, Kaj Blennow et al. The Lancet profile →
  3. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    2009 1.6k citations Leslie M. Shaw, Hugo Vanderstichele et al. Annals of Neurology profile →
  4. Gut microbiome alterations in Alzheimer’s disease
    2017 1.5k citations N. Vogt, Andrew P. Merluzzi et al. Scientific Reports profile →
  5. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    2010 1.4k citations Kaj Blennow, Harald Hampel et al. Nature Reviews Neurology profile →
  6. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
    2016 1.4k citations Bob Olsson, Ronald Lautner et al. The Lancet Neurology profile →
  7. Neurofilaments as biomarkers in neurological disorders
    2018 1.3k citations Charlotte E. Teunissen, Fredrik Piehl et al. Nature Reviews Neurology profile →
  8. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
    2006 1.3k citations Oskar Hansson, Henrik Zetterberg et al. The Lancet Neurology profile →
  9. Alzheimer's disease
    2015 1.2k citations Colin L. Masters, Randall J. Bateman et al. profile →
  10. Clearance systems in the brain—implications for Alzheimer disease
    2015 1.2k citations Roxana O. Carare, Ricardo S. Osorio et al. Nature Reviews Neurology profile →
  11. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
    2016 1.2k citations Clifford R. Jack, David A. Bennett et al. Neurology profile →
  12. The Amyloid-β Pathway in Alzheimer’s Disease
    2021 1.1k citations Harald Hampel, John Hardy et al. Molecular Psychiatry profile →
  13. CSF markers for incipient Alzheimer's disease
    2003 976 citations Kaj Blennow, Harald Hampel The Lancet Neurology profile →
  14. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
    2017 811 citations Kaj Blennow, Henrik Zetterberg et al. Annals of Neurology profile →
  15. Neurofilament light chain as a biomarker in neurological disorders
    2019 791 citations Lorenzo Gaetani, Kaj Blennow et al. Journal of Neurology Neurosurgery & Psychiatry profile →
  16. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
    2020 749 citations Shorena Janelidze, Niklas Mattsson et al. profile →
  17. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
    2017 691 citations Niklas Mattsson, Ulf Andréasson et al. JAMA Neurology profile →
  18. tau protein in cerebrospinal fluid
    1995 635 citations Kaj Blennow, Anders Wallin et al. profile →
  19. Biomarkers for Alzheimer's disease: current status and prospects for the future
    2018 634 citations Kaj Blennow, Henrik Zetterberg Journal of Internal Medicine profile →
  20. An 18-Year Follow-up of Overweight and Risk of Alzheimer Disease
    2003 617 citations Deborah Gustafson, Elisabet Rothenberg et al. Archives of Internal Medicine profile →
  21. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
    2021 588 citations Bruno Dubois, Giovanni B. Frisoni et al. The Lancet Neurology profile →
  22. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
    2008 584 citations Lars Lannfelt, Kaj Blennow et al. The Lancet Neurology profile →
  23. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
    2017 574 citations Sebastian Palmqvist, Michael Schöll et al. Nature Communications profile →
  24. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
    1999 563 citations Frank Hulstaert, Kaj Blennow et al. Neurology profile →
  25. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
    2016 540 citations Ulf Andréasson, Åsa Sandelius et al. Clinical Chemistry and Laboratory Medicine (CCLM) profile →
  26. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
    2010 537 citations Juha O. Rinne, David J. Brooks et al. The Lancet Neurology profile →
  27. The Neuropathology and Neurobiology of Traumatic Brain Injury
    2012 512 citations Kaj Blennow, John Hardy et al. profile →
  28. CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
    2018 477 citations Oskar Hansson, Erik Stomrud et al. Alzheimer s & Dementia profile →
  29. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
    2010 468 citations Harald Hampel, Richard Frank et al. Nature Reviews Drug Discovery profile →
  30. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
    2019 467 citations Niklas Mattsson, Nicholas Cullen et al. JAMA Neurology profile →
  31. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
    2018 457 citations Harald Hampel, Sid E. O’Bryant et al. Nature Reviews Neurology profile →
  32. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood
    2013 441 citations Henrik Zetterberg, Kaj Blennow et al. Nature Reviews Neurology profile →
  33. Plasma β-amyloid in Alzheimer’s disease and vascular disease
    2016 439 citations Shorena Janelidze, Erik Stomrud et al. Scientific Reports profile →
  34. CSF and blood biomarkers for Parkinson's disease
    2019 436 citations Lucilla Parnetti, Lorenzo Gaetani et al. The Lancet Neurology profile →
  35. Traumatic brain injuries
    2016 423 citations Kaj Blennow, Ann C. McKee et al. profile →
  36. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
    2017 407 citations Philip Scheltens, Bruno Dubois et al. Alzheimer s Research & Therapy profile →
  37. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
    2021 382 citations Nicholas J. Ashton, Tharick A. Pascoal et al. Acta Neuropathologica profile →
  38. Plasma tau in Alzheimer disease
    2016 374 citations Niklas Mattsson, Henrik Zetterberg et al. Neurology profile →
  39. Current state of Alzheimer’s fluid biomarkers
    2018 372 citations José Luís Molinuevo, Jeffrey L. Cummings et al. Acta Neuropathologica profile →
  40. Blood-based NfL
    2017 352 citations Oskar Hansson, Shorena Janelidze et al. Neurology profile →
  41. Amyloid biomarkers in Alzheimer's disease
    2015 351 citations Kaj Blennow, Niklas Mattsson et al. profile →
  42. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
    2015 349 citations Magnus Gisslén, Richard W. Price et al. EBioMedicine profile →
  43. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
    2015 344 citations Henrik Zetterberg, Tobias Skillbäck et al. JAMA Neurology profile →
  44. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
    2017 321 citations Lenka Novakova, Henrik Zetterberg et al. Neurology profile →
  45. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
    2016 318 citations Shorena Janelidze, Henrik Zetterberg et al. profile →
  46. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
    2016 317 citations Jonathan D. Rohrer, Ione Woollacott et al. Neurology profile →
  47. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
    2021 317 citations Sebastian Palmqvist, Pontus Tideman et al. profile →
  48. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
    2021 300 citations Joana B. Pereira, Shorena Janelidze et al. Brain profile →
  49. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
    2019 296 citations Sebastian Palmqvist, Shorena Janelidze et al. JAMA Neurology profile →
  50. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
    2021 285 citations Giovanni B. Frisoni, Daniele Altomare et al. Nature reviews. Neuroscience profile →
  51. Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link
    2018 282 citations Jaime Ramos‐Cejudo, Thomas Wısnıewskı et al. EBioMedicine profile →
  52. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
    2021 270 citations Pratishtha Chatterjee, Steve Pedrini et al. Translational Psychiatry profile →
  53. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
    2021 263 citations Shorena Janelidze, Charlotte E. Teunissen et al. JAMA Neurology profile →
  54. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports
    2017 248 citations Pashtun Shahim, Henrik Zetterberg et al. Neurology profile →
  55. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
    2022 239 citations Shorena Janelidze, Nicholas J. Ashton et al. Brain profile →
  56. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
    2019 224 citations Sebastian Palmqvist, Philip S. Insel et al. profile →
  57. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
    2020 217 citations Thomas K. Karikari, Andréa Lessa Benedet et al. Molecular Psychiatry profile →
  58. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
    2020 211 citations Niklas Mattsson, Emelie Andersson et al. profile →
  59. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
    2020 207 citations Tara L. Spires‐Jones, Henrik Zetterberg et al. Alzheimer s Research & Therapy profile →
  60. Developing the ATX(N) classification for use across the Alzheimer disease continuum
    2021 200 citations Harald Hampel, Jeffrey L. Cummings et al. Nature Reviews Neurology profile →
  61. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
    2021 185 citations Claudia Cicognola, Shorena Janelidze et al. Alzheimer s Research & Therapy profile →
  62. Blood biomarkers for Alzheimer’s disease in clinical practice and trials
    2023 184 citations Oskar Hansson, Kaj Blennow et al. Nature Aging profile →
  63. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
    2022 162 citations Thomas K. Karikari, Nicholas J. Ashton et al. Nature Reviews Neurology profile →
  64. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
    2021 146 citations Michelle M. Mielke, Jeffrey L. Dage et al. JAMA Neurology profile →
  65. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
    2023 144 citations Niklas Mattsson, Gemma Salvadó et al. JAMA Neurology profile →
  66. Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
    2022 130 citations Nicholas J. Ashton, Kaj Blennow et al. Acta Neuropathologica profile →
  67. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
    2022 127 citations Fernando González‐Ortiz, Michael Turton et al. Brain profile →
  68. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
    2022 122 citations Shorena Janelidze, Nicholas Cullen et al. Alzheimer s & Dementia profile →
  69. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
    2023 113 citations Fernando González‐Ortiz, Przemysław R. Kac et al. Molecular Neurodegeneration profile →
  70. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
    2023 110 citations Harald Hampel, Jeffrey L. Cummings et al. profile →
  71. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years
    2022 107 citations Joel Simrén, Ulf Andréasson et al. Brain Communications profile →
  72. Postoperative delirium and changes in the blood–brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study
    2022 102 citations Jennifer Taylor, Margaret Parker et al. British Journal of Anaesthesia profile →
  73. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
    2023 94 citations Wagner S. Brum, Nicholas Cullen et al. Nature Aging profile →
  74. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
    2023 85 citations Gemma Salvadó, Rik Ossenkoppele et al. profile →
  75. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
    2024 35 citations Federica Ribaldi, Aurélien Lathuilière et al. Journal of Neurology profile →
  76. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
    2024 32 citations Joseph Therriault, Nicholas J. Ashton et al. EBioMedicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Kaj Blennow 65.5k 41.1k 33.2k 24.1k 22.0k 2.0k 121.6k
Henrik Zetterberg 46.1k 0.7× 28.2k 0.7× 26.0k 0.8× 22.2k 0.9× 16.9k 0.8× 2.0k 94.9k
Dennis W. Dickson 48.4k 0.7× 22.3k 0.5× 25.1k 0.8× 39.8k 1.6× 23.8k 1.1× 1.3k 103.1k
John Q. Trojanowski 69.7k 1.1× 26.6k 0.6× 46.2k 1.4× 59.7k 2.5× 29.3k 1.3× 1.1k 151.1k
Bradley T. Hyman 60.4k 0.9× 24.2k 0.6× 32.4k 1.0× 14.8k 0.6× 21.0k 1.0× 728 113.5k
David M. Holtzman 53.5k 0.8× 20.6k 0.5× 27.1k 0.8× 8.4k 0.4× 23.5k 1.1× 580 99.1k
Ronald C. Petersen 51.2k 0.8× 60.9k 1.5× 12.8k 0.4× 17.1k 0.7× 18.1k 0.8× 1.1k 116.2k
John C. Morris 43.9k 0.7× 47.8k 1.2× 15.0k 0.5× 9.5k 0.4× 15.0k 0.7× 999 115.5k
Bruce L. Miller 28.8k 0.4× 31.8k 0.8× 16.1k 0.5× 25.3k 1.0× 12.3k 0.6× 1.1k 90.0k
David A. Bennett 32.3k 0.5× 28.3k 0.7× 16.2k 0.5× 8.3k 0.3× 12.6k 0.6× 1.3k 85.4k
Philip Scheltens 36.3k 0.6× 43.7k 1.1× 10.5k 0.3× 12.9k 0.5× 18.1k 0.8× 1.2k 99.9k

Countries citing papers authored by Kaj Blennow

Since Specialization
Citations

This map shows the geographic impact of Kaj Blennow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaj Blennow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaj Blennow more than expected).

Fields of papers citing papers by Kaj Blennow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaj Blennow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaj Blennow. The network helps show where Kaj Blennow may publish in the future.

Co-authorship network of co-authors of Kaj Blennow

This figure shows the co-authorship network connecting the top 25 collaborators of Kaj Blennow. A scholar is included among the top collaborators of Kaj Blennow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaj Blennow. Kaj Blennow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas E. Starzl Breakdown of academic impact, for papers by Yong Zhang Breakdown of academic impact, for papers by Alan R. Katritzky Breakdown of academic impact, for papers by Wenping Hu Breakdown of academic impact, for papers by Joel Schwartz Breakdown of academic impact, for papers by Li Song Breakdown of academic impact, for papers by Claudiu T. Supuran Breakdown of academic impact, for papers by Yong Sik Ok
Rankless by CCL
2026